The INNOVANCE® Antithrombin Assay is a state-of-the-art reagent for the detection of congenital or acquired antithrombin deficiencies. The ready-to-use reagent offers improved onboard stability and, due to its Xa-based activity, shows excellent sensitivity to detect antithrombin mutations.
INNOVANCE Antithrombin AssayState-of-the-art antithrombin testing
Did this information help you?
1
Not available for sale in the U.S.
2
More information on the assay’s sensitivity can be found in the brochure.
3
Dependent upon individual analyzer performance.
4
Translation of recommendations for prevention of thrombosis in cases of SARS-CoV-2 (COVID-19) of the office for research in thrombosis and hemostasis (Empfehlungen zur Thromboseprophylaxe bei SARS-CoV-2 (COVID-19) der GTH Geschäftsstelle).
5
Various recommendations and guidelines, such as “Empfehlungen zur Thromboseprophylaxe bei SARS-CoV-2 (COVID-19) der GTH Geschäftsstelle” (local german guideline), may vary from country to country.
Assay performance can vary from country to country as well as with the system application of the respective assay. The values listed above are provided as examples only.
Product availability varies from country to country and is subject to varying regulatory requirements.
Atellica, BCS, INNOVANCE, PSI, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. Sysmex is a trademark of Sysmex Corporation. All other trademarks and brands are the property of their respective owners.